| Genmab A/S | 2,722.00 / -0.18% |
| Date/Time | 06/18 / 16:59 |
| Chg. / Chg.(%) | -5.00 / -0.18% |
| Bid | 2,728.00 / 126 |
| Ask | 2,730.00 / 31 |
| Open | 2,711.00 |
| Previous Close | 2,727.00 |
| High | 2,760.00 |
| Low | 2,696.00 |
| Volume [DKK] | 692,289,901.00 |
| Volume [Units] | 266,244 |
| Price fixings | 8443 |
| ISIN | DK0010272202 |
| Security | GMAB |
| Exchange | OMX Nordic |
| Type | Stock |
Other Exchanges
| Exchange | Last | Volume | |
|---|---|---|---|
| Lang & Schwa.. | 359.80 |  |
|
| OMX Nordic | 2,722.00 | |
266,244 |
| London Inter.. | 2,746.0 | |
51,779 |
| Cboe Europe .. | 2,730.00 | |
46,661 |
| Turquoise | 2,730.00 | |
17,267 |
| Nasdaq Other.. | 425.4900 |  |
75 |
| Frankfurt | 366.8000 | |
41 |
| TradeGate | 366.000 | |
21 |
| Cboe Europe .. | 2,729.50 | |
15 |
| Cboe Europe .. | 2,717.00 | |
2 |
| Vienna Globa.. | 364.40 | |
0 |
| München | 365.50 | |
0 |
| Düsseldorf | 363.20 | |
0 |
| Berlin | 364.90 | |
0 |
| Stuttgart | 362.400 | |
0 |
| Quotrix | 363.4000 | |
|
| gettex | 367.100 | |
|
| Mexico | 8,850.31 |  |
62 |
News
- BioNTech Announces First Patient Dosed in Phase 2 Clinical Trial of mRNA-based BNT111 in Patients with Advanced Melanoma
06/18/2021 / 11:00 - GlobeNewswire - Pfizer and BioNTech to Provide 500 Million Doses of COVID-19 Vaccine to U.S. Government for Donation to Poorest Nations
06/10/2021 / 08:00 - GlobeNewswire - Genmab and Bolt Biotherapeutics Announce Oncology Research and Development Collaboration
06/02/2021 / 14:00 - GlobeNewswire - Pfizer and BioNTech Receive First Authorization in European Union for COVID-19 Vaccine in Adolescents
05/28/2021 / 21:45 - GlobeNewswire - Genmab Announces that Janssen has Received Positive CHMP Opinion Recommending DARZALEX® (daratumumab) Subcutaneous (SC) Formulation for Patients with Newly Diagnosed Light-chain (AL) Amyloidosis
05/21/2021 / 15:08 - GlobeNewswire
Real-time